miemss optional supplemental protocols › documents › narcan protocol training.pdf ·...
TRANSCRIPT
![Page 1: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/1.jpg)
March 26, 2016 1
MIEMSS Optional Supplemental Protocols
Presented by: Joshua P. Young NRP
![Page 2: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/2.jpg)
Naloxone Optional Supplemental Program
March 26, 2016 2
![Page 3: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/3.jpg)
Intra-Nasal Naloxone for BLS Providers
• Key Points as listed in the Protocols effective July 1, 2015.
March 26, 2016 3
![Page 4: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/4.jpg)
Intra-Nasal Naloxone for BLS Providers
• Indications for administration
Ø Patient suffering from Respiratory Depression caused by a known or suspected Opioid/Narcotic overdose.
March 26, 2016 4
![Page 5: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/5.jpg)
Intra-Nasal Naloxone for BLS Providers
• Contraindications
Ø None clinically significant in Adult patients.
Ø Patients < 28 days old
March 26, 2016 5
![Page 6: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/6.jpg)
Intra-Nasal Naloxone for BLS Providers
• Verify prior to administration that
ü Naloxone is in date ü Patient meets criteria in protocol for
Naloxone administration ü Should be administered and titrated so
respiratory efforts return, but not intended to restore full consciousness.
March 26, 2016 6
![Page 7: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/7.jpg)
Intra-Nasal Naloxone for BLS Providers
• Medication supplied in Bristojet packaging 2 mg Naloxone Hydrochloride in 2 ml
March 26, 2016 7
![Page 8: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/8.jpg)
Intra-Nasal Naloxone for BLS Providers
• Preparation procedure – Open packaging – Remove Glass Vial, and Bristojet device – Remove cap on end of glass vial – Remove cap on end of Bristojet device – Gently screw glass vial of medication on
Bristojet device
March 26, 2016 8
![Page 9: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/9.jpg)
Intra-Nasal Naloxone for BLS Providers
• Preparation continued – Attach Mucosal Atomization device to
Bristojet
March 26, 2016 9
![Page 10: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/10.jpg)
Intra-Nasal Naloxone for BLS Providers
• Administration Procedure – Place tip of mucosal atomization device
in the nostril and briskly push the plunger forward, administering half of the total volume of medication (up to a MAXIMUM of 1 mL per nostril), occluding opposite nostril. – Repeat previous step in the other nostril,
delivering the remaining half of the medication.
March 26, 2016 10
![Page 11: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/11.jpg)
Intra-Nasal Naloxone for BLS Providers
• Post administration
– Patient should be monitored for response to Naloxone administration.
– Patients responding to naloxone may require additional doses and transportation to the hospital since most Opioids/Narcotics last longer than Naloxone. Mechanism of action has duration of 40 minutes.
March 26, 2016 11
![Page 12: MIEMSS Optional Supplemental Protocols › documents › Narcan Protocol Training.pdf · Intra-Nasal Naloxone for BLS Providers • Key Points as listed in the Protocols effective](https://reader030.vdocuments.site/reader030/viewer/2022041116/5f284c867a92fa1f00232baf/html5/thumbnails/12.jpg)
Intra-Nasal Naloxone for BLS Providers
• Continued patient management – Continue supportive care during transport.
Medical consultation required for
additional doses to maintain respiratory activity.
March 26, 2016 12